416 results on '"Cascavilla, N."'
Search Results
2. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
3. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)
4. Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature
5. “Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”
6. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
7. P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
8. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
9. PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
10. P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS
11. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
12. P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
13. P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
14. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
15. Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
16. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
17. Allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory multiple myeloma: possible cures and acceptable toxicities: AB97
18. Total body irradiation (TBI)-based versus chemotherapybased myeloablative conditioning regimen before allogeneic stem cell transplantation (allo-sct) for acute myeloid leukemia (AML). A single centre experience: AB59
19. Haploidentical stem cell transplantation followed by highdose cyclophosphamide post transplant as GVHD prophylaxis in high-risk haematologic malignancies: a retrospective multicentric experience from the REP (Rete Ematologica Pugliese): AB24
20. PIXANTRONE (PIX) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). REAL LIFE EXPERIENCE IN 27 PATIENTS
21. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia
22. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)
23. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
24. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
25. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study
26. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
27. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
28. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
29. Lenalidomide as salvage therapy in a case of relapse after allogeneic HSCT in a patient with myelodysplatic syndrome with isolated 5q deletion (5q-): R1541
30. Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia
31. TEAM (Thiotepa, Etoposide, Cytarabine, Melphalan) as conditioning regimen for lymphoma treatment with autologous haematopoietic stem cell transplantation: P860
32. Melphalan, prednisone, lenalidomide versus melphalan (200 mg/m2) and autologous transplantation in newly diagnosed myeloma patients: a phase III trial: 0272
33. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency
34. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura
35. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
36. Allotransplant after autologous haematopoietic stem cell transplantation relapse in aggressive lymphoma patients: update af a retrospective GITMO study: O256
37. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451
38. Bortezomib or Lenalidomide to Treat Disease Relapse After Allogeneic Transplantation in Myeloma: A426
39. Radioimmunotherapy with haemopoietic stem cell transplantation for treatment of malignant non-Hodgkin lymphoma: multicentre study on thirty patients
40. Allotransplant as salvage therapy after autologous haematopoietic stem cell transplantation relapse in diffuse large B cell lymphoma patients: a retrospective GITMO study
41. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
42. Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer
43. PF174 GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL
44. PB2130 REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA
45. PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS
46. PB1901 IBRUTINIB, SINGLE AGENT BTK INHIBITOR, FOR RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD EXPERIENCE FROM RETE EMATOLOGICA PUGLIESE (REP).
47. PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY
48. PF644 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
49. BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMAS: A RETROSPECTIVE EXPERIENCE BY THE RETE EMATOLOGICA PUGLIESE (REP)
50. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.